Monument Therapeutics Announces Partnership with Foundation for the National Institutes of Health for Clinical Trial of MT1988, a Novel Treatment for Schizophrenia
Schizophrenia is a severe mental health disorder and ranks among the top 15 leading causes of disability worldwide. It is characterized by a range of symptoms, including auditory and visual hallucinations, delusions, and cognitive impairments that affect attention, memory, reasoning, and processing speed. Many individuals begin to show signs of schizophrenia months or even years before receiving a diagnosis. This period, referred to as the 'clinical high risk' (CHR) phase, is currently without effective treatment options, despite its profound impact on functioning and quality of life.
This Investigational New Drug (IND)-opening clinical trial for MT1988 is the first patient trial from Monument's precision medicine pipeline. The randomized, placebo-controlled study will enroll 150 CHR participants, who will receive one of two dose levels of MT1988 or placebo over an eight-week treatment period. The trial is on track to begin dosing in the autumn of 2025.
The study will evaluate the potential of MT1988 to improve cognitive symptoms in CHR individuals, incorporating a range of clinical and cognitive biomarkers including Monument's proprietary digital biomarker. This approach is designed to assess not only therapeutic effects but also the potential of these biomarkers to predict and monitor treatment response.
The trial is part of the FNIH-managed Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ) program, a public-private partnership between the National Institutes Health (NIH) and private sector organizations, including major pharmaceutical companies and nonprofit groups. The program seeks to accelerate the development of more effective treatments for schizophrenia and related mental health conditions. It is supported by NIH grants awarded by the National Institute of Mental Health (NIMH) to Yale School of Medicine (U01MH137298) and Brigham and Women's Hospital (U24MH137171), representing a $44 million investment so far.
The clinical trial with MT1988 will be co-led by Dr. Scott Woods and Dr. Youngsun Cho from Yale School of Medicine, Dr. Carrie Bearden from University of California, Los Angeles (UCLA), Dr. John Kane from Northwell Health, Dr. Martha Shenton and Dr. Ofer Pasternak from Brigham and Women's Hospital, Dr. Sylvain Bouix from École de technologie supérieure, Université du Québec, and Dr. Rene Kahn from Icahn School of Medicine at Mount Sinai. This distinguished team brings together diverse expertise across psychiatry, neuroscience, and data science, highlighting a unified commitment to advancing early intervention for schizophrenia.
Dr. Kiri Granger, Chief Scientific Officer of Monument Therapeutics, commented: 'This trial marks an exciting milestone for Monument to evaluate MT1988 in a patient population with our proprietary digital biomarker. Studying individuals at clinical high risk allows us to explore early cognitive changes and support the advancement of personalised treatment approaches in early-stage illness. We are thrilled to partner with FNIH and leading investigators on a study that represents a major step forward in developing meaningful treatment options for people at risk of schizophrenia.'
About Monument Therapeutics:
Monument Therapeutics is a neuroscience-focused drug development company headquartered in Manchester, UK. It applies a unique novel drug development strategy, leveraging digital assessments of cognition to select patients suitable for treatment with new innovative drugs.
For more information, please visit www.monumenttx.com.
About the Foundation for the National Institutes of Health: The Foundation for the National Institutes of Health (FNIH) builds public-private partnerships that connect leading biomedical scientists at the National Institutes of Health (NIH) with their counterparts in life sciences companies, academia, patient organizations, foundations, and regulatory agencies (including the U.S. Food and Drug Administration and European Medicines Agency). Through team science, the FNIH solves complex health challenges and accelerates breakthroughs for patients, regardless of who they are or what health threats they face. The FNIH contributes to the development of new therapies, diagnostics, and potential cures; advances global health; and helps train the next generations of scientists. Established by Congress in 1990 to support the mission of the NIH, the FNIH is a not-for-profit 501(c)(3) charitable organization. For more information about the FNIH, please visit fnih.org.
About the Accelerating Medicines Partnership®: Launched in 2014 and managed by the FNIH, the Accelerating Medicines Partnership (AMP) program brings together the National Institutes of Health, U.S. Food and Drug Administration, biomedical and life sciences companies, nonprofits, patient-focused groups, and other organizations to transform the current model for developing new diagnostics and treatments. Using cutting-edge scientific approaches and broad sharing of research data, all AMPs seek to improve understanding of disease pathways, facilitate better selection of targets for drug development, and streamline processes for bringing new treatments to patients. To learn more about AMP, visit fnih.org/AMP.
For further information, contact:
Jenny Barnett, CEO
E: jbarnett@monumenttx.com
Media inquiries:
Christopher Koddermann
Tel: +41 (79) 434 25 78
E-mail: chris@cura-communications.com
Logo – https://mma.prnewswire.com/media/2750517/Monument_Therapeutics_Logo.jpg
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malaysian Reserve
a day ago
- Malaysian Reserve
Monument Therapeutics Announces Partnership with Foundation for the National Institutes of Health for Clinical Trial of MT1988, a Novel Treatment for Schizophrenia
MANCHESTER, England, Aug. 19, 2025 /PRNewswire/ — Monument Therapeutics, a stratified medicine company, today announced a partnership with the Foundation for the National Institutes of Health (FNIH) to evaluate MT1988, a novel treatment in development for cognitive impairment associated with schizophrenia, in a proof of principle clinical trial. Schizophrenia is a severe mental health disorder and ranks among the top 15 leading causes of disability worldwide. It is characterized by a range of symptoms, including auditory and visual hallucinations, delusions, and cognitive impairments that affect attention, memory, reasoning, and processing speed. Many individuals begin to show signs of schizophrenia months or even years before receiving a diagnosis. This period, referred to as the 'clinical high risk' (CHR) phase, is currently without effective treatment options, despite its profound impact on functioning and quality of life. This Investigational New Drug (IND)-opening clinical trial for MT1988 is the first patient trial from Monument's precision medicine pipeline. The randomized, placebo-controlled study will enroll 150 CHR participants, who will receive one of two dose levels of MT1988 or placebo over an eight-week treatment period. The trial is on track to begin dosing in the autumn of 2025. The study will evaluate the potential of MT1988 to improve cognitive symptoms in CHR individuals, incorporating a range of clinical and cognitive biomarkers including Monument's proprietary digital biomarker. This approach is designed to assess not only therapeutic effects but also the potential of these biomarkers to predict and monitor treatment response. The trial is part of the FNIH-managed Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ) program, a public-private partnership between the National Institutes Health (NIH) and private sector organizations, including major pharmaceutical companies and nonprofit groups. The program seeks to accelerate the development of more effective treatments for schizophrenia and related mental health conditions. It is supported by NIH grants awarded by the National Institute of Mental Health (NIMH) to Yale School of Medicine (U01MH137298) and Brigham and Women's Hospital (U24MH137171), representing a $44 million investment so far. The clinical trial with MT1988 will be co-led by Dr. Scott Woods and Dr. Youngsun Cho from Yale School of Medicine, Dr. Carrie Bearden from University of California, Los Angeles (UCLA), Dr. John Kane from Northwell Health, Dr. Martha Shenton and Dr. Ofer Pasternak from Brigham and Women's Hospital, Dr. Sylvain Bouix from École de technologie supérieure, Université du Québec, and Dr. Rene Kahn from Icahn School of Medicine at Mount Sinai. This distinguished team brings together diverse expertise across psychiatry, neuroscience, and data science, highlighting a unified commitment to advancing early intervention for schizophrenia. Dr. Kiri Granger, Chief Scientific Officer of Monument Therapeutics, commented: 'This trial marks an exciting milestone for Monument to evaluate MT1988 in a patient population with our proprietary digital biomarker. Studying individuals at clinical high risk allows us to explore early cognitive changes and support the advancement of personalised treatment approaches in early-stage illness. We are thrilled to partner with FNIH and leading investigators on a study that represents a major step forward in developing meaningful treatment options for people at risk of schizophrenia.' About Monument Therapeutics: Monument Therapeutics is a neuroscience-focused drug development company headquartered in Manchester, UK. It applies a unique novel drug development strategy, leveraging digital assessments of cognition to select patients suitable for treatment with new innovative drugs. For more information, please visit About the Foundation for the National Institutes of Health: The Foundation for the National Institutes of Health (FNIH) builds public-private partnerships that connect leading biomedical scientists at the National Institutes of Health (NIH) with their counterparts in life sciences companies, academia, patient organizations, foundations, and regulatory agencies (including the U.S. Food and Drug Administration and European Medicines Agency). Through team science, the FNIH solves complex health challenges and accelerates breakthroughs for patients, regardless of who they are or what health threats they face. The FNIH contributes to the development of new therapies, diagnostics, and potential cures; advances global health; and helps train the next generations of scientists. Established by Congress in 1990 to support the mission of the NIH, the FNIH is a not-for-profit 501(c)(3) charitable organization. For more information about the FNIH, please visit About the Accelerating Medicines Partnership®: Launched in 2014 and managed by the FNIH, the Accelerating Medicines Partnership (AMP) program brings together the National Institutes of Health, U.S. Food and Drug Administration, biomedical and life sciences companies, nonprofits, patient-focused groups, and other organizations to transform the current model for developing new diagnostics and treatments. Using cutting-edge scientific approaches and broad sharing of research data, all AMPs seek to improve understanding of disease pathways, facilitate better selection of targets for drug development, and streamline processes for bringing new treatments to patients. To learn more about AMP, visit For further information, contact: Jenny Barnett, CEO E: jbarnett@ Media inquiries: Christopher Koddermann Tel: +41 (79) 434 25 78 E-mail: chris@ Logo –
Malaysian Reserve
6 days ago
- Malaysian Reserve
Sports Research® Launches Sam's Club Exclusive in Tempe, Arizona
Bringing Premium Wellness to the Desert's Innovation Capital TEMPE, Ariz., Aug. 14, 2025 /PRNewswire/ — Sports Research®, a leader in premium health and wellness supplements, is proud to announce the exclusive in-store release of two of its most advanced products at Sam's Club in Tempe, Arizona. Following the Grand Opening on August 7, Tempe shoppers will be the first in the country to get these best-selling Sports Research formulations. Magtein® Magnesium L-Threonate – 120 ct: One of the most clinically researched forms of magnesium that's been shown to cross the blood-brain barrier and support cognitive function.* Organic Collagen Peptides – 34 servings: The World's First Organic Collagen Peptides® – a sustainable product that offers support for healthy hair, skin, nails and joints.* This launch represents more than a regional rollout, it's a bold new model for how science-driven wellness meets everyday access. Tempe consumers are effectively being handed the power to lead what's next for 600+ Sam's Clubs nationwide. 'We are excited to introduce Sports Research Products to the Sam's Club Member,' said Abid Shivji, VP of Business Development and Strategy at Sports Research. 'This collaboration reflects our shared commitment to innovation and quality, ultimately paving the way for more accessible wellness solutions for consumers nationwide.' This is the first time Sports Research products have launched exclusively at a Sam's Club, underscoring a broader strategy: to bring top quality, transparent wellness solutions to the warehouse channel, with one influential, health-conscious community at the forefront. 'Starting in Tempe, we're building momentum for national growth, one cart, one customer, one community at a time. This release is not just about new products, it's about celebrating a passion for the wellness culture in Arizona,' said Dr. Jamie Wemette, Wholesale Director at Sports Research. 'We're not just launching in Sam's Club. We're launching a new era in our Generation Wellness Movement: Legacy meets accessibility.' With premium ingredients, trusted sourcing, and quality formulations, Sports Research is committed to making wellness essentials that work for everyone. Whether you're a fitness enthusiast, a busy parent, a health professional, or someone just starting your wellness journey, the launch offers access to high-quality supplements typically reserved for specialty or online channels. The Tempe Sam's Club is now stocking these exclusive products in-store, with availability coming soon to and select clubs nationwide. * These Statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. About Sports Research Since 1980, Sports Research has been a family-owned company driven by a legacy of health. Starting with the breakthrough of its flagship product, Sweet Sweat, Sports Research has expanded to offer a diverse range of wellness solutions for all generations. At the heart of Sports Research is a commitment to quality, sourcing only the finest ingredients and materials from around the world. Many of these ingredients are backed by rigorous scientific research, reflecting the brand's dedication to efficacy and innovation. Sports Research empowers individuals to live their best lives with products they can trust. Discover the difference wisdom and quality make by exploring the full product lineup at For Sports Research media inquiries, interviews, or product samples, please contact: Sports Research Communications Team: communications@
Malaysian Reserve
6 days ago
- Malaysian Reserve
Synergy Spine Solutions Appoints Troy Wahlenmaier as Chief Commercial Officer
LOUISVILLE, Colo., Aug. 14, 2025 /PRNewswire/ — Synergy Spine Solutions Inc., a leading innovator in artificial cervical disc replacement, today announced the appointment of Troy Wahlenmaier as Chief Commercial Officer (CCO). In this role, Mr. Wahlenmaier will lead global sales and marketing efforts as the company accelerates its growth and prepares for U.S. commercialization. With more than 30 years of commercial leadership in the medical device industry, Mr. Wahlenmaier brings deep expertise in scaling high-performance sales organizations, executing successful commercialization strategies, and driving sustained revenue growth. Mr. Wahlenmaier joins Synergy following a distinguished 13-year tenure at SI-BONE, where he served as Senior Vice President of U.S. Sales. Under his leadership, SI-BONE's U.S. revenue grew an average of 20% annually, reaching a projected $188 million in 2025. He built and led a commercial team of over 200 professionals and a robust distributor network, while also playing a key role in delivering SI-BONE's first quarter of positive Adjusted EBITDA and cash flow breakeven – marking a major milestone in the company's commercial evolution. 'Troy brings a proven track record of commercial success in innovative spinal implants and medical technologies,' said Josh Butters, Chief Executive Officer of Synergy Spine Solutions. 'He's a visionary leader with a rare blend of strategic focus and people-first leadership. His ability to build scalable, culture-driven commercial teams will be pivotal as we accelerate growth and prepare for U.S. market entry.' Throughout his career, Mr. Wahlenmaier has held leadership roles at top medical device companies including NuVasive, Kyphon, SpineTech, and United States Surgical Corporation. He has consistently exceeded revenue targets by developing market-leading teams and navigating the complexities of both private and public company environments. His experience spans early-stage commercialization, market development, and operational execution. 'I'm thrilled to join Synergy Spine Solutions at such a pivotal and transformative time,' said Mr. Wahlenmaier. 'The company's commitment to innovation and improving patient outcomes aligns perfectly with my passion for building high-impact commercial teams. I look forward to working with the entire Synergy team to expand our market presence and deliver sustained value to our customers, partners, and shareholders.' Mr. Wahlenmaier holds a Bachelor of Business Administration from Wichita State University and resides in Colorado. About Synergy Spine Solutions The Vision of Synergy Spine Solutions is to identify and commercialize innovative spine technologies that help surgeons improve their patients' quality of life and advance the standard of care. The company's flagship product, the Synergy Disc®, is the only device that is designed to restore both motion and alignment to the spine. For media inquiries, please contact:Tim HeinVP of Sales and Marketingtimhein@ +1 360 991 6300https:// Logo – View original content:
